患者报告疲劳改善高危骨髓增生异常综合征预后:MDS-CAN研究
该加拿大MDS注册研究验证了FA-IPSS(h)模型,该模型结合EORTC QLQ-C30疲劳评分(阈值≥45分)与IPSS高危分层可区分不同生存亚组。
要点
- FA-IPSS(h)模型结合EORTC QLQ-C30疲劳评分(≥45分)与IPSS高危分层,可区分不同生存亚组。
- 自报疲劳可改善高危MDS患者的总生存预测,支持将患者报告结局纳入整体评估。
核心结论
- 自报疲劳可改善高危MDS患者的总生存预测,支持将患者报告结局纳入整体评估。
主要发现
- FA-IPSS(h)模型结合EORTC QLQ-C30疲劳评分(阈值≥45分)与IPSS高危分层,可将患者分为生存结局不同的亚组。
关键数值与推荐
- FA-IPSS(h)模型中疲劳阈值:EORTC QLQ-C30评分≥45分。
- 疲劳评估工具:EORTC QLQ-C30和ESAS全球疲劳量表(GFS)。
临床怎么用
- 在高危MDS评估中可纳入患者自报疲劳(如EORTC QLQ-C30或ESAS GFS)以细化生存预测。
- FA-IPSS(h)模型可用于IPSS高危患者,结合疲劳评分进行风险分层。
- ESAS GFS单条目疲劳量表更易于临床部署,可作为疲劳评估的简化工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The incorporation of patient-reported outcomes with traditional disease risk classification was found to strengthen survival prediction in patients with myelodysplastic syndromes (MDS). In the present Canadian MDS registry analysis, we validate a recently reported prognostic model, the Fatigue-International Prognostic Scoring System among higher-risk patients [FA-IPSS(h)], which incorporates patients' reported fatigue, assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30), with a threshold of ≥45 points, in higher IPSS score, stratifying them into distinct subgroups with different survival outcomes. We further validated this concept, using the Revised IPSS >3·5 as cut-off for the definition of higher-risk MDS, and patients' reported fatigue according to Edmonton Symptom Self-Assessment Scale (ESAS) Global Fatigue Scale (GFS), a single-item fatigue rating scale, which is easier to deploy. This emphasises the power of self-reported fatigue at refining overall survival predictions in higher-risk MDS and further bolsters the importance of considering patient-related outcomes in global assessments.
引用
- Amitai I, Geddes M, Zhu N, et al. Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study. Br J Haematol. 2021. PMID: 34060069. doi:10.1111/bjh.17537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。